RBD – Past, Present, Future Webcast 2021 (Part 1 and Part 2) On-Demand-RBD – Past, Present, Future Part 2 Webcast 2021 On-Demand

Video Transcription

Video Summary

The transcript of the video discussed the associations between REM behavior disorder (RBD) and neurodegeneration, as well as the significance of the RBD population for upcoming clinical trials. The first part of the webinar introduced the speaker and discussed the format of the webinar, which consisted of three pre-recorded talks and a live Q&A session at the end. The second part of the webinar featured Dr. Ronald Postuma, who spoke about RBD as a window into other neurodegenerative diseases, such as Parkinson's disease and dementia with Lewy bodies. He discussed the role of synuclein and how RBD can be used as a diagnostic marker for synuclein-specific neurodegenerative disorders. He also highlighted the prognostic and predictive value of RBD in these diseases. The third speaker, Dr. Ambra Stefani, discussed biomarkers of neurodegeneration within RBD. She emphasized the importance of selecting appropriate patients for clinical trials and discussed potential biomarkers for disease, progression, short-term phenoconversion, and type of phenoconversion. The final speaker, Dr. Alex Videnovich, discussed the challenges and opportunities in conducting clinical trials for RBD, both for symptomatic care and disease modification. He emphasized the need for well-defined patients and appropriate outcome measures in clinical trials. The webinar concluded with a live question and answer session with the speakers.

Keywords

REM behavior disorder

neurodegeneration

RBD population

clinical trials

synuclein

Parkinson's disease

dementia with Lewy bodies

biomarkers

diagnostic marker

prognostic value